AzTrials
AzTrials

Coronary AngiographyREPEATNCT05340998

Radial accEss Crossover for PErcutaneous Coronary Procedures And ouTcome: the REPEAT Study

An observational study of Coronary Angiography and Percutaneous Coronary Intervention, run by Ospedale Sandro Pertini, Roma at 10 sites in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

All patients who undergo to percutaneous coronary diagnostic or interventional procedures through transradial access (TRA) will be screened for inclusion in this prospective observational study and patients with TRA failure necessitating vascular crossover will be included in the Registry after signing a dedicated… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Transradial access for percutaneous coronary procedures
Type of treatment
Surgery or procedure
How many people
1,357 participants
Where
10 sitesItaly
Study dates
15 Jul 2022to 16 Jan 2025
How long will I take part?
6 Days
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with an indication to percutaneous coronary procedures performed through transradial approach

Who may be able to join

  • All patients who undergo to percutaneous coronary diagnostic or interventional procedures through transradial access

Who cannot join

  • Lack of signed informed consent, age <18 years

Trial locations and contacts

10 sites in 1 country.

10 sites in 1 country

Italy10 sites
  • Ospedale di Avezzano

    Avezzano

  • Ospedale S. Andrea

    Roma

  • Ospedale S. Camillo

    Roma

  • Ospedale Sandro Pertini

    Roma

  • Ospedale Santo Spirito

    Roma

  • Policlinico Agostino Gemelli

    Roma

  • Policlinico Umberto I

    Roma

  • Ospedale di Sassari

    Sassari

  • Ospedale di Teramo

    Teramo

  • Ospedale di Trento

    Trento

Other trials in Italy

About this study

All patients who undergo to percutaneous coronary diagnostic or interventional procedures through transradial access (TRA) will be screened for inclusion in this prospective observational study and patients with TRA failure necessitating vascular crossover will be included in the Registry after signing a dedicated written informed consent. A Control group of consecutive patients with radial access and without crossover will be included. Primary end point of the study is the rate of in-hospital vascular complications and major bleeding in crossover vs non crossover groups

Read the detailed description

All patients who undergo to percutaneous coronary diagnostic or interventional procedures through transradial approach (TRA) will be screened for inclusion in this prospective observational study and patients with TRA failure necessitating vascular crossover will be included in the Registry after signing a dedicated written informed consent. A Control group of consecutive patients with radial access and without crossover will be enrolled (2:1 rate compared to crossover group to avoid possible selection bias) after signing a dedicated written informed consent.

The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion.

According to the selected secondary access, patients will be divided in two groups: patients with a secondary (or tertiary) wrist access (total wrist Group) and patients with a crossover to femoral (Femoral Group). Patients included in the total wrist group may have a secondary access to the ulnar artery (ipsilateral or contralateral) or to the contralateral radial.

All patients will be checked during the procedure, immediately after and 24 hour post to evaluate possible vascular complications and bleeding.

Patient baseline characteristics, hospital data, comorbid conditions and complications will be recorded in a dedicated electronic case report form.

Exclusion criteria will be: lack of signed informed consent, age <18 years.

Primary End point of the study is the rate of in-hospital vascular complications and major bleeding in crossover vs non crossover groups.

Secondary End-points are:

  • The rate of vascular complications or bleeding in total wrist vs femoral Group.
  • The rate of minor bleeding
  • Procedure duration
  • Fluoroscopy time
  • Number of catheters employed
  • Differences among operators and Centers

Vascular complications are defined as any vascular damage clinically documented as vessel perforation, arterial-venous fistula, pseudoaneurysm, arterial dissection, retroperitoneal hematoma and compartmental syndrome. Major bleeding complications are defined according to the BARC classification, as BARC 3 (overt bleeding plus a hemoglobin drop > 3 g/dL; any transfusion with overt bleeding, cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring intravenous vasoactive agents and intracranial haemorrhage) and BARC 5 (fatal bleeding).

Minor bleeding is defined as Hematoma larger than 10 cm not requiring medical intervention (Easy III)

Being tested
Transradial access for percutaneous coronary procedures

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transradial access for percutaneous coronary proceduresProcedure or surgery

    Transradial approach for percutaneous coronary procedures. The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion

Study groups in NCT05340998
Study groupRoleWhat they receive
Crossover GroupPatients with Transradial access failure for percutaneous coronary procedures necessitating vascular crossover
Receives: Procedure: Transradial access for percutaneous coronary procedures
Non Crossover GroupPatients with successful transradial access for percutaneous coronary procedures
Receives: Procedure: Transradial access for percutaneous coronary procedures

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Vascular complications and major bleeding

    The rate of in-hospital vascular complications and major bleeding in crossover vs non crossover groups

    Measured: up to seven days

Secondary outcomes (1)
  1. Minor bleeding

    The rate of minor bleeding in crossover vs non crossover groups

    Measured: up to seven days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Apr 2022
  2. Study start15 Jul 2022
  3. Primary completion15 Jan 2025
  4. Study completion16 Jan 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
1,357 participants (actual)
Target duration
6 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT05340998
Sponsor's protocol ID
Pertini06
Acronym
REPEAT
Status last verified
Mar 2025
First submitted
14 Apr 2022
Last updated
13 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Coronary Angiography and Percutaneous Coronary Intervention, run by Ospedale Sandro Pertini, Roma at 10 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Vascular complications and major bleeding (time frame: up to seven days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in